درصد تخفیف نوروزی ویژه کارگاه و فیلم‌های آموزشی

اصول تنظیم قراردادها

پروپوزال نویسی

آموزش مهارت های کاربردی در تدوین و چاپ مقاله

پیش
Prevention and Management of Mucositis in Patients With Cancer: a Review Article

Fatemeh Owlia¹, Seid kazem Kazemeini², Neda Gholami¹

Abstract
After chemo/radiation therapy, mucositis is one of the most common side effects, so timely nursing care and instructed home care, significantly could decrease cost of medical care, and then increase quality of life.

This review summarizes preventive and therapeutic intervention of mucositis (localized or systemic), between some of patients with cancer.

Keywords: Mucositis; Radiotherapy; Primary prevention; Therapeutics

Please cite this article as: Owlia F, Kazemeini SK, Gholami N. Prevention and Management of Mucositis in Patients With Cancer: a Review Article. Iran J Cancer Prev.2012; 5(4): 216-20.

Introduction
Oral complications after high doses of chemotherapy and radiation therapy during the Hematopoietic Stem Cell Transplantation (HSCT) cause high morbidity and could affect transplant outcome [1]. Oral Mucositis (OM) leave one of the worst impressions on medical and economic success of HSCT [2]. The rupture of oral cavity's epithelial defense due to the cytotoxic effect of the myeloablative regimen, together with the submucosal involvement, lead to several clinical events, such as opportunistic infections, pain, and difficulties in mastication and swallowing [3,4]. This might result in severe nutritional deficiencies, then cause to parenteral nutrition and more hospitalization. All these factors significantly affect the patient's quality of life and patient costs. "OM" has seen most often in: very young-very old and female patients with cancer. Then "myeloblative regimen" and "type of transplant" have been the other important risk factors for "OM" [5]. Mucositis evolution recognizes not only through direct cell injury mediated by chemotherapy or radiation, but also more significantly as a consequence of a complex cascade of biological events [6]. Regarding to the type of transplant, there are evidences that patients which have submitted to allogeneic transplant develop OM more frequently and more severely than autologous transplant patients. About 75% of allogeneic transplanted patients will show severe OM. This could be due to the cytotoxic drugs that have used for prevention of Graft Versus Host Disease (GVHD), which are highly toxic to the mucosal cells. These medicines have reduced the regenerative capacity of the oral mucosa thereby prolonging the mucositis and increasing its severity [7]. There is no consensus about the most efficient protocol to prevent and treat OM. Several treatments have been testing, including the use of a keratinocyte growth factor, benzydamine; mouth rinses with antimicrobial agents such as chlorhexidine; and cryo or laser therapy during chemotherapy [8, 9]. Regardless of selected treatment, meticulous oral hygiene is essential for OM control [10].

Considering mucositis as a systemic process, rather than limited one, provides supports for use of systemic treatments instead of merely oral rinses [5]. Application of laser therapy reduces the extension and severity of oral mucositis in patients after hematopoietic transplant [1].

Analgesics like morphine have recommended for oral mucositis in hematopoietic stem cell transplant patients. Sucralfate and antimicrobial lozenges have not recommended for prevention of radiation-induced oral mucositis. Benzydamine has recommended for radiation-induced mucositis in patients with head and neck cancer receiving moderate-dose therapy. Cryotherapy has recommended for bolus 5-Fluourouracil (5-FU) then
has suggested for bolus edatrexate and high-doses of melphalan. Keratinocyte growth factor-1 (palifermin) has recommended 3 days before conditioning treatment then 3 days post transplant for patients whose have received high-dose chemotherapy and total body irradiation with autologous stem cell transplant in hematologic malignancies. Granulocyte-macrophage colony stimulating factor mouthwashes have not recommended for prevention of mucositis.

Recommendations for oral care include:

1. Collaborate with a multidisciplinary team in all phases of treatment.
2. Brush all tooth surfaces for at least 90 seconds, at least twice daily by a soft toothbrush.
3. Allow toothbrushes to air dry before storing.
4. Floss at least once daily or as advised by clinician.
5. Rinse mouth four times daily with a bland rinse.
6. Avoid tobacco, alcohol, irritating foods (acidic, hot, rough, and spicy).
7. Use water-based moisturizers to protect lips.
8. Maintain adequate hydration.
9. Provide written instruction and training for patients about the above items. Verify understanding with return explanation and demonstration.

Bland rinses (normal saline, sodium bicarbonate, and a saline and sodium bicarbonate mixture) to remove loose debris and aid with oral hydration have also recommended in stem cell transplantation [3, 11].

If feasible, establish formal protocols and guidelines that are adaptable, appropriate and efficient for:

- Adults
- Children
- Elderly
- Patients with cognitive or sensory impairment

Before cancer therapy, optimize oral health:

- Consider evaluation by dental professional
- Eliminate/reduce oral infections, periodontal disease, gingivitis, deep caries/pulp infections
- Remove/modify potential sources of trauma/irritation
- Sharp teeth/fractured restorations
- Poorly fitting or broken removable dentures
- Orthodontic brackets or wires
- Reduce risk for secondary infection [12]

As there is no universally accepted medical or hygienic solution for prevention of mucositis, treatment of the problems experienced by patients with mucositis is an area for nursing intervention. Three important areas of focus include: treatment of pain, dryness, and ulcerations [13].

Treatment of Pain

Although topical coating agents might be initially effective for pain relief of limited superficial lesions and morphine mouthwash has examined as a topical treatment, considering mucositis as a systemic process provides theoretical support for the use of systemic modes of pain relief associated with severe mucositis [14-19].

Treatment of Dryness

Non-irritating rinses, sucking ice, and sips water might be perceived as beneficial. Mouth moisturizers may also promote comfort [20].

Treatment of Ulcerations

Frequent rinsing with a non-irritating solution is extremely important and might decrease risk of septicemia. However, patient’s compliance would strongly depended on the quality of the pain control [3]. The most effective self-care behaviors for Radiation Therapy (RT)-induced mucositis pain were mouth rinsing and oral analgesics usage [21].

Animal trials data and preliminary data in patients indicate that cytokines such as interleukin-1, interleukin-11, Transforming Growth Factor beta 3 (TGF-b3) and keratinocyte growth factor could reduce the incidence of mucositis. Other potentially useful agents are the angiogenesis-inhibiting medicines; thalidomide, the cytoprotector; amifostine and the pineal hormone; melatonin [22].

It is estimated that oral mucositis is a complication in 40% of patients receiving chemotherapy, 75% of those exposed to high doses of chemotherapy and more than 90% of those irradiated for head and neck cancer [23,24]. Ulcerative mucositis not only is extremely painful, but also constitutes a risk for systemic infections, especially in neutropenic patients. The pathophysiology of mucositis has not known in detail. Irradiation and chemotherapeutic agents such as 5-fluorouracil and methotrexate, could induce a direct toxic effect on the oral mucosa, but in patients receiving other types of chemotherapy, mucositis is most often have pronounced during the period of febrile neutropenia [25]. Furthermore mucositis is due to oral infections in a number of patients [26].

Recently, a new hypothesis for development of chemotherapy-induced stomato toxicity has proposed. According to this, mucositis is a complex process, which has divided into four phases, called the inflammatory phase, the epithelial phase, the ulcerative: bacteriological phase and the healing phase. This hypothesis also has denoted on the importance of various cytokines in the development and treatment of mucositis. A number of locally
applied agents have been investigated to prevent or treat mucositis. These include sucralfate, vitamin E, chlorhexidine, anti-inflammatory agents, cytokines, Prostaglandin E1 (PGE-1) and PGE-2, multi agents topical mouth rinses, leucovorin and allopurinol. Systemically applied treatments for mucositis, investigated in trials include antioxidants (b-carotene, azelastine), immune modulatory drugs such as indomethacin and pentoxifylline, anticholinergic drugs, cytokines, antiviral drugs and glutamine. The anti cholinergic medicine propantheline has been able to decrease etoposide-induced mucositis, compared with placebo or historical controls, in small studies [27]. Acyclovir is effective in prevention of reactivation of HSV and reduces incidence of oral ulcerations, but does not influence overall oral toxicity or the need for antibiotics [19]. Cryotherapy has caused local vasoconstriction and thereby reduces blood flow of the oral mucosa. Drugs currently under investigation include keratinocyte growth factor, interleukin-1 and 11 and TGF-b. Both the cytoprotector, amifostine and the pineal hormone; melatonin have been claimed to have some effects in the prevention of mucositis. It has denoted that the potential mechanism of "c thalidomide" action might include inhibition of cytokines such as interleukin-1, interleukin-6 and TNF-a, that are supposed to take part in the pathogenesis of oral mucositis [28].

The literature indicates that honey could promote wound healing, so the authors have investigated whether its anti-inflammatory properties might limit the severity of radiation-induced oral mucositis. Honey is strongly protective (RR = 0.067) against the development of mucositis. The proportion of patients with intolerable oral mucositis was lower in the honey group and this was statistically significant (p = 0.000). Honey is readily available, affordable and well accepted by patients, making it useful for improving the quality of life in irradiated patients [29].

Oral Pilocarpine (OP) is highly effective in the prevention of oral mucositis when given prophylactically to adult patients receiving a variety of cancer chemotherapy regimens. It should notice that pilocarpine is a parasympathicomimetic medicine should be prescribed cautiously, because of side effects such as stomach ache, nausea, tachycardia and extreme sweating. Reasons for this positive effect are not clear. OP is known to increase salivary flow by stimulating the salivary glands, especially the minor salivary glands. Minor salivary glands are responsible for production of 70% of the total salivary mucin. OP stimulates the production of salivary mucin, proteins and glycoproteins. It seems

| Table 1. Patient-related factors cause to worse mucositis |
|----------------------------------|
| **Age** | Very young: increased turn over | Very old: decreased healing |
| **Gender** | A mild trend to female |
| **Oral hygiene** | Poor Oral hygiene |
| **Salivary secretory function** | Decreased flow rate or quality of saliva |
| **Smoking** | Change microbial flora | Delayed healing |
| **Body mass index** | Poor nourished people |
| **Genetic** | Some patients are resistant to mucositis |
| **Renal capacity** | Elevated creatinine leads to mucotoxicity |
| **Previous chemotherapy** | Weakness of mucosa because of previous mucositis |

| Table 2. Recommendations for mucositis management |
|----------------------------------|
| **Solutions for mucositis problem** | **Prevention for mucositis** |
| Pain relief | Treatment of dryness | Treatment of ulceration | Oral pilocarpine |
| Topical coating agent | Non irritating rinses | Sucking ice | Non irritating solutions |
| Morphin mouthwash | Sipping water | | GMCSF not recommended |
that mucin and other salivary constituents play a protective role in prevention of chemotherapy-induced mucositis [30, 31].

Nowadays a novel preventive agent for mucositis, is a milk-derived protein extract (pv701) in form of mouthwash. This agent is used in patients with lymphoma who were given carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy. Simultaneously initiating with BEAM regimen, this agent has administered as 1215 mg/day, 6 times daily for 12 days then continue for one week after chemotherapy. It should note in patients who have received autologus stem cell after BEAM has been completed. In comparison, patient who has received pv701 experienced significantly less frequent higher grades of mucositis. Duration of admission to intensive care unit and enteral/parenteral feeding was significantly reduced [32, 33].

On the other hand some of the previously preventive prescribed medicines currently have demonstrated not only no significant benefit but also serious complications [34-37]. Makkonen has reported no advantages from subcutaneously administration of 150-300 microgram Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) after 10 Gy radiotherapy. His study has shown 65% skin reaction in injection site, 30% fever, 25% bone pain and 15% nausea [38].

Its worthy of mention, regarding that mucositis is unavoidable in patients after chemo/radiation therapy, it is advisable to improve quality of life and decrease the severity of complications with timely nursing care and palliative medicines.

Acknowledgment
We are grateful to members of Department of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences for instruction in design of this study.

Conflict of Interest
There is no conflict of interest in this article.

Authors’ Contribution
Fatemeh owlia designed the study, reviewed the literatures and wrote the paper. Seid Kazem Kazemeini contributed to literature review and Neda gholami contributed to writing the manuscript. All authors read and approved the final manuscript.

References
1. Paula Eduardo FD, Bezinelli LM, Estacio Orsi MC, Rodrigues M, Ribeiro MS, Hamerschlag N, et al. The influence of dental care associated with laser therapy on oral mucositis during autologous hematopoietic cell transplant: retrospective study. einstein. 2011; 9(2 Pt 1):201-6.
2. Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009; 45(12):1015-20.
3. Greenberg M, Glick M, Ship J. Burket’s oral medicine diagnosis & treatment. 11th edition. Hamilton. BC Decker inc. 2008; 178-82.
4. McGuire DB, Peterson DE, Muller S, Muller S, Owen DC, Slomons MF, et al. The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest. 2002; 20:893-903.
5. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005; 11(5):383-8.
6. Sonis ST. New thoughts on initiation of mucositis. Oral Diseases. 2010; 16; 597-600.
7. Robien KJ, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 2004; 22:1268-75.
8. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109(5):820-31.
9. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010; 46(6):452-6.
10. Peterson DE, Bensadoun RJ, Rolla F. ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2010; 21(5):261-5.
11. Porozov S, Cahalon L, Weiser M, Branski D, Lider O, Oberbaum M. Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medicine Traumeel S. Clin Dev Immunol. 2004; 11:143-9.
12. Oral Mucositis, Care Guide – FINAL 12/2010.
13. Ellers J, Million R. Clinical update: prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs. 2011; 27(4):1-16.
14. Quinn B, Stone R, Uhlenhopp M, McCann S, Blijlevens N. Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit. Eur J Oncol Nurs. 2007; 11:S10-8.
15. Andersson P, Persson L, Hallberg IR, Renvert S. Testing an oral assessment guide during chemotherapy in a Swedish care setting: a pilot study. J Clin Nurs. 1999; 8:150-8.
16. DeWalt EM, Haines AK. The effects of specified stressors on healthy oral mucosa. Nurs Res. 1969; 18:22-7.
17. Barker GJ, Epstein JB, Williams KB, Gorsky M, Raber-Durlacher JE. Current practice and knowledge of oral care for cancer patients: a survey of supportive
health care providers. Support Care Cancer. 2005; 13:32-41.
18. Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology. [http://www.mascc.org/mc/page.do?sitePageId¼88037. accessed July 25, 2011.]
19. Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database of Syst Rev. 2004:CD001973:2002.
20. Sonis ST, Eilers JG, Epstein JB, LeVeque FG, Liggett WH Jr, Mulagha MT. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group Cancer. 1999; 85:2103-13.
21. Wong PC, Dodd MJ, Miaskowski C, Paul SM, Bank KA, Shibah GH, et al. Mucositis pain induced by radiation therapy: prevalence, severity, and use of self-care behaviors. J Pain Symptom Manage. 2006; 32(1):27-37.
22. Herrstedt J. Prevention and management of mucositis in patients with cancer. Int J Antimicrob Agents. 2000; 16(2):161-3.
23. Quinn B, Potting CMJ, Stone R, Bijlevens NMA, Monica Fliedner M, Margulies A, et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. EUROPEAN JOURNAL OF CANCER. 2008; 44: 61 -72.
24. Lilley K, Garcia P, Gooley T, McDonnell P, Taber R, Holmberg L, et al. A prospective, randomized study of cryotherapy in patients undern -going autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 2006; 37:1031-5.
25. Stokman MA, Sonis ST, Dijkstra PU, Burgerhof JGM, Spijkervet FKL. Assessment of oral mucositis in clinical trials: impact of training on evaluators in a multi-centre trial. Eur J Cancer. 2005; 41:1735-8.
26. Epstein JB, Epstein JD, Epstein MS, Oien H, Truelove EL. Oral doxepin rinses: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth Analg. 2006; 103:465-70.
27. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34:39-43.
28. NCI Monograph. Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention and Treatment. 1990; 9:3-8.
29. Khanal B, Ballig M, Uppal N. Effect of topical honey on limitation of radiation-induced oral mucositis: an intervention study. Int J Oral Maxillofac Surg. 2010; 39(12):1181-5.
30. Stiff PJ, Emmanouilides CH, Bensinger WI, Gentile T, Blazar B, Shea TC, et al. Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting. Journal of clinical pathology.2006; 24:5186-93.
31. Awidi A, Homsi U, Kakali R, Mubarak A, Hassan A, Kelta M, et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. Eur J Cancer. 2001; 37(16):2010-4.
32. Prince HM, Regester G, Jones P, Jablohkski L, Seymour JF, Lillie K, et al. A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy. Biol Blood Marrow Transplant. 2005; 11(7):512-20.
33. Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shibah G, et al. Radiationinduced mucositis: a randomized clinical trial of micronized sucralose versus salt & soda mouthwashes. Cancer Invest. 2003; 21:21-33.
34. Awwad HK, Lottayef M, Shoeman T, Begg AC, Wilson G, Bentzen SM, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer. 2002; 86(4):517-23.
35. Dodd MJ, Larson PJ, Dibble SL. Randomized clinical trial of chlorhexidine versus placebo for preventionof oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 1996; 23(6):921-7.
36. Sutherland SE, Brownan GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys. 2001; 49(4):917-30.
37. Duncan GG, Epstein JB, Tu D, Bezjak A, Ottaway J, Pater J, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005; 27(5):421-8.
38. Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joensuu H, et al. Granulocyte macrophage-colony stimulating factor [GM-CSF] and sucralose in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys. 2000; 46(3):525-34.
۳۰ درصد تخفیف نوروزی ویژه کارکاهه و فیلم‌های آموزشی

اصول تنظیم قراردادها
پروپوزال نویسی
آموزش مهارت‌های کاربردی در ندوین و چاپ مقاله